Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 524

1.

Controversies in the Treatment of Classical Hodgkin Lymphoma.

Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A.

Hemasphere. 2018 Oct;2(5):e149. doi: 10.1097/HS9.0000000000000149. Epub 2018 Oct 2.

2.

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma.

Borchmann S, Engert A.

Oncotarget. 2018 Dec 25;9(101):37462-37463. doi: 10.18632/oncotarget.26486. eCollection 2018 Dec 25. No abstract available.

3.

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group.

Bröckelmann PJ, Müller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezek H, Balakumaran A, Raut MK, Engert A, von Tresckow B.

Ann Oncol. 2019 Mar 1;30(3):490-491. doi: 10.1093/annonc/mdz004. No abstract available.

PMID:
30657863
4.

Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.

Sud A, Thomsen H, Law PJ, Försti A, da Silva Filho MI, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Lightfoot T, Kane E, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Nat Commun. 2019 Jan 8;10(1):157. doi: 10.1038/s41467-018-08105-w.

5.

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.

Sasse S, Reddemann K, Diepstra A, Borchmann S, Oschlies I, Schnitter A, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e45-e46. doi: 10.3324/haematol.2018.207829. No abstract available.

6.

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.

Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG).

Br J Haematol. 2019 Apr;185(1):42-52. doi: 10.1111/bjh.15741. Epub 2018 Dec 28.

PMID:
30592027
7.

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Kreissl S, Goergen H, Müller H, Meissner J, Mehnert A, Bürkle C, Fuchs M, Engert A, Behringer K, Borchmann P; German Hodgkin Study Group.

Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1540781. [Epub ahead of print]

PMID:
30507313
8.

Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.

von Tresckow B, Sayehli C, Aulitzky WE, Goebeler ME, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A.

Eur J Haematol. 2019 Feb;102(2):163-173. doi: 10.1111/ejh.13188. Epub 2019 Jan 7.

PMID:
30347469
9.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
10.

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.

Sud A, Thomsen H, Orlando G, Försti A, Law PJ, Broderick P, Cooke R, Hariri F, Pastinen T, Easton DF, Pharoah PDP, Dunning AM, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N, Campa D; PRACTICAL Consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Blood. 2018 Nov 8;132(19):2040-2052. doi: 10.1182/blood-2018-06-855296. Epub 2018 Sep 7.

11.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B.

Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.

PMID:
30168134
12.

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.

Blood. 2018 Nov 22;132(21):2273-2279. doi: 10.1182/blood-2018-05-852129. Epub 2018 Aug 30.

PMID:
30166329
13.

Hodgkin Lymphoma in Adults.

Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N.

Dtsch Arztebl Int. 2018 Aug 6;115(31-32):535-540. doi: 10.3238/arztebl.2018.0535.

14.

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).

Borchmann S, Müller H, Haverkamp H, Baues C, Marková J, Hüttmann A, Glunz A, Fuchs M, Borchmann P, Engert A.

Leukemia. 2019 Feb;33(2):439-446. doi: 10.1038/s41375-018-0240-8. Epub 2018 Aug 21.

PMID:
30131583
15.

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W.

Haematologica. 2019 Jan;104(1):e21-e24. doi: 10.3324/haematol.2018.196279. Epub 2018 Aug 3. No abstract available.

16.

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.

PMID:
30064977
17.

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18.

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.

Ann Oncol. 2018 Sep 1;29(9):1926-1931. doi: 10.1093/annonc/mdy250.

PMID:
30010775
18.

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).

Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N.

Cochrane Database Syst Rev. 2018 Jul 12;7:CD012556. doi: 10.1002/14651858.CD012556.pub2. Review.

PMID:
30001476
19.

Hodgkin lymphoma in elderly patients.

Borchmann S, Engert A, Böll B.

Curr Opin Oncol. 2018 Sep;30(5):308-316. doi: 10.1097/CCO.0000000000000464. Review.

PMID:
29994901
20.

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.

Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, von Tresckow B.

J Clin Oncol. 2018 Sep 1;36(25):2603-2611. doi: 10.1200/JCO.2018.78.7192. Epub 2018 Jul 10.

PMID:
29989855

Supplemental Content

Loading ...
Support Center